UV Blood Irradiation for Health & Longevity - Quick Reference Sheet

UV Blood Irradiation for Health & Longevity

Created on 08/11/2026 – Quick Reference based on Evidence Review created using AI4L / Grok 4 Audit

Ultraviolet blood irradiation draws a small fraction of blood, exposes it to ultraviolet light outside the body, then returns it. Historical infection use and modern clinic interest outpace controlled evidence. For longevity-oriented adults it remains experimental—not a validated lifespan therapy—with mainly needle-site issues and short-lived flu-like fatigue. (Full Review)

Protocol

Classic Knott-style volume
~3.5 mL/kg (5–7% blood volume)
Withdrawn, UV-exposed, reinfused (often 60–200 mL)
Session frequency
1–3 sessions per week
Several weeks, then as-needed maintenance
Wavelength
UVC ~253.7 nm
Classic mercury-quartz; confirm modern device specs
Time to effect
Acute infection signal
24–48 hours
Historical series (uncontrolled)
Chronic / wellness goals
Weeks
Assessed over multi-session courses

Benefits

Contraindications
  • Uncontrolled porphyria or severe photosensitivity disorders (pending specialist clearance)
  • Pregnancy
  • Active untreated bacteremia with unstable sepsis (when standard critical care is the priority)
  • Severe anemia or inability to tolerate planned extracorporeal blood-draw volume
  • Known allergy to tubing or cuvette materials
  • Inability to obtain safe venous access
Key Interactions
  • Photosensitizing drugs (tetracyclines, fluoroquinolones, sulfonamides, amiodarone, thiazides, retinoids)
  • Anticoagulants and antiplatelet agents (warfarin, DOACs, aspirin, clopidogrel)
  • Photosensitizing or immune-active supplements (e.g., St. John's wort)
  • Antihypertensives and volume-depleting agents
  • Glucose-lowering drugs (insulin, sulfonylureas)
  • Concurrent ozone or high-dose oxidative IV therapies
  • Immunosuppressants

Risk & Side Effects

  • High:
  • Medium: Procedure-related local effects; Transient flu-like symptoms and post-treatment fatigue
  • Low: Systemic reactions in treatment series
  • Speculative: Excess oxidative modification of plasma proteins at high UV dose; Theoretical DNA stress in host cells

Monitoring

Marker Target Why
CBC with differential Individual baseline; investigate unexplained cytopenias Infection response and procedural blood-loss tolerance
CRP (hs-CRP) Often <1.0 mg/L in optimization contexts General inflammation trend
CMP (glucose, electrolytes, renal, hepatic enzymes) Glucose mid-normal fasting; eGFR stable for age; liver enzymes near personal baseline Safety around sessions; liver context if viral hepatitis history
Indication-specific viral load or culture data Per disease guidelines Objective infection endpoint when relevant
Blood pressure and orthostatic vitals Individual optimal; no symptomatic drop Detect hypotension risk

Cadence: Clinical check each visit; labs at ~4 weeks and course end; every 3–6 months if courses repeat

Qualitative Assessment

  • Post-session recovery time (target resolution of flu-like symptoms within 24–48 hours)
  • Energy and exercise tolerance across the treatment week
  • Sleep quality and daytime alertness
  • Disease-specific symptom scores (e.g., joint pain, respiratory symptoms) when applicable